A Single Center, Randomized, Parallel Safety Study To Evaluate The Immunogenicity Of A Novel Glucagon Formulation Compared To Commercially Available Glucagon Administered By Intramuscular Injection In Adults With Type 1 OR Type 2 Diabetes

Trial Profile

A Single Center, Randomized, Parallel Safety Study To Evaluate The Immunogenicity Of A Novel Glucagon Formulation Compared To Commercially Available Glucagon Administered By Intramuscular Injection In Adults With Type 1 OR Type 2 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2016

At a glance

  • Drugs Glucagon (Primary) ; Glucagon (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Registrational
  • Sponsors AMG Medical
  • Most Recent Events

    • 22 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinialTrials.gov record.
    • 19 Nov 2014 Planned End Date changed from 1 Apr 2014 to 1 Dec 2014, according to ClinialTrials.gov record.
    • 19 Nov 2014 Status changed from recruiting to active, no longer recruiting, according to ClinialTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top